These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6716398)

  • 41. Effects of methyl acetyl phosphate, a covalent antisickling agent, on the density profiles of sickle erythrocytes.
    Ueno H; Yatco E; Benjamin LJ; Manning JM
    J Lab Clin Med; 1992 Jul; 120(1):152-8. PubMed ID: 1613320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
    Kennedy PE; Williams FL; Abraham DJ
    J Med Chem; 1984 Feb; 27(2):103-5. PubMed ID: 6694161
    [No Abstract]   [Full Text] [Related]  

  • 43. Sickle hemoglobin aggregation: a new class of inhibitors.
    Votano JR; Gorecki M; Rich A
    Science; 1977 Jun; 196(4295):1216-9. PubMed ID: 870976
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methyl acetyl phosphate, a new type of antisickling agent: site-specific acetylating agent toward the 2,3-DPG binding site in hemoglobin S.
    Ueno H; Manning JM
    Am J Pediatr Hematol Oncol; 1988; 10(4):348-50. PubMed ID: 3239714
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.
    Beddell CR; Goodford PJ; Kneen G; White RD; Wilkinson S; Wootton R
    Br J Pharmacol; 1984 Jun; 82(2):397-407. PubMed ID: 6733364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pyridyl derivatives of benzaldehyde as potential antisickling agents.
    Nnamani IN; Joshi GS; Danso-Danquah R; Abdulmalik O; Asakura T; Abraham DJ; Safo MK
    Chem Biodivers; 2008 Sep; 5(9):1762-9. PubMed ID: 18816529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of hydroxyurea in sickle cell disease.
    Halsey C; Roberts IA
    Br J Haematol; 2003 Jan; 120(2):177-86. PubMed ID: 12542474
    [No Abstract]   [Full Text] [Related]  

  • 49. Specific chemical modifications in the beta-cleft site of hemoglobin. Potential anti-sickling agents with hybrid functionalities.
    Klotz IM; Haney DN; Wood LE
    J Biol Chem; 1985 Dec; 260(30):16215-23. PubMed ID: 4066708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. O2 dependence of K+ transport in sickle cells: the effect of different cell populations and the substituted benzaldehyde 12C79.
    Gibson JS; Khan A; Speake PF; Ellory JC
    FASEB J; 2001 Mar; 15(3):823-32. PubMed ID: 11259401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, and testing of potential antisickling agents. 7. Ethacrynic acid analogues.
    Abraham DJ; Mehanna AS; Williams FS; Cragoe EJ; Woltersdorf OW
    J Med Chem; 1989 Nov; 32(11):2460-7. PubMed ID: 2810334
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regioselective covalent modification of hemoglobin in search of antisickling agents.
    Park S; Hayes BL; Marankan F; Mulhearn DC; Wanna L; Mesecar AD; Santarsiero BD; Johnson ME; Venton DL
    J Med Chem; 2003 Mar; 46(6):936-53. PubMed ID: 12620071
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of Aptamers That Bind to Sickle Hemoglobin and Inhibit Its Polymerization.
    Purvis SH; Keefer JR; Fortenberry YM; Barron-Casella EA; Casella JF
    Nucleic Acid Ther; 2017 Dec; 27(6):354-364. PubMed ID: 29039727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The antisickling role of uric acid in sickle cell disease.
    Ekeke GI; Nduka N
    Trop Geogr Med; 1987 Apr; 39(2):152-6. PubMed ID: 3629708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polymerization of sickle cell hemoglobin at arterial oxygen saturation impairs erythrocyte deformability.
    Green MA; Noguchi CT; Keidan AJ; Marwah SS; Stuart J
    J Clin Invest; 1988 Jun; 81(6):1669-74. PubMed ID: 3384944
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of pH on the rheologic and antisickling effects of dimethyl adipimidate.
    Pennathur-Das R; Lande WM; Mentzer WC; Mohandas N; Preisler H; Kleman KM; Heath RH; Lubin BH
    J Lab Clin Med; 1984 Nov; 104(5):718-29. PubMed ID: 6491469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts).
    Dean J; Schechter AN
    N Engl J Med; 1978 Oct; 299(16):863-70. PubMed ID: 692579
    [No Abstract]   [Full Text] [Related]  

  • 59. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 60. Extracorporeal treatment of erythrocytes in sickle cell anemia: hemoglobin carbamylation.
    Diederich D; Curran M; Odenbaugh A; Diederich A; Core E
    Tex Rep Biol Med; 1980-1981; 40():313-22. PubMed ID: 7323976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.